Lumateperone deuterated - Intra-Cellular Therapies
Alternative Names: ITI 1284; ITI-1284 ODT-SLLatest Information Update: 17 May 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Intra-Cellular Therapies
- Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Organic deuterium compounds; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
- Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Agitation; Generalised anxiety disorder; Psychotic disorders
- No development reported Behavioural disorders; Dementia; Depressive disorders
Most Recent Events
- 11 Apr 2024 Intra-Cellular Therapies initiates a phase-I trial (In volunteers) in USA in March 2024 (Sublingual, Tablet) (NCT06299410)
- 11 Mar 2024 Intra-Cellular Therapies plans a phase-I trial (In volunteers) in USA in March 2024 (Sublingual, Tablet) (NCT06299410)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Behavioural-disorders(In the elderly, In volunteers, In adults) in USA (Sublingual, Tablet)